RMD: Q1 revenue grew 7% core CC as EPS rose 14% and shareholder returns exceeded $1B
ResMed Inc. reported Q1 revenue of $1.4B, up 7% on a core constant currency basis, with non-GAAP EPS rising 14% to $2.91. The company returned over $1B to shareholders and maintained FY27 guidance.
How this was made
The 30-second read
Why it matters
The earnings beat and sizable buyback are likely to drive short‑term upside, while unchanged FY27 guidance tempers long‑term expectations.
Market read
Earnings release provides fresh data for traders; the beat and buyback create a clear short‑term trading catalyst.
What to watch
Potential headwinds from reimbursement pressures and competitive pricing.
Background
ResMed (RMD) reported its Q1 2026 results, highlighting revenue growth, EPS beat, and a $1B shareholder return program.
Ticker impact
Q1 revenue of $1.4B and non‑GAAP EPS of $2.91 were disclosed, marking a 7% revenue increase and 14% EPS rise.
upward pressure as the market prices in the earnings beat and $1B buyback
The new earnings numbers exceed prior expectations and are accompanied by a large buyback, which typically supports the stock price.
Market effects
Strong performance may lift other sleep‑apnea and medical‑device peers.
Positive for US healthcare equipment sector.
Limited to investors focused on US med‑tech stocks.
Counterpoint
If guidance remains unchanged, the rally could be short‑lived amid broader market weakness.
Key entities
- companyResMed Inc.
US‑listed medical‑device maker focusing on sleep‑apnea solutions.
